Archive


Category: Albert Bourla

  • FDA finds ‘no evidence’ that second Pfizer pill stops repeat COVID-19 symptoms

    While Pfizer’s COVID-19 antiviral Paxlovid does offer a reduction in hospitalization and deaths, there is currently “no evidence” to suggest that prolonging and repeating a course of the drug has any more benefit according to an FDA official. John Farley, director of the Food and Drug Administration’s (FDA) Office of Infectious Diseases, said on Wednesday […]